Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK. Gross MI, et al. Among authors: demo sd. Mol Cancer Ther. 2014 Apr;13(4):890-901. doi: 10.1158/1535-7163.MCT-13-0870. Epub 2014 Feb 12. Mol Cancer Ther. 2014. PMID: 24523301
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.
Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Momcilovic M, et al. Among authors: demo s. Cancer Cell. 2018 May 14;33(5):905-921.e5. doi: 10.1016/j.ccell.2018.04.002. Cancer Cell. 2018. PMID: 29763624 Free PMC article.
Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.
Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Momcilovic M, et al. Among authors: demo s. Cell Rep. 2017 Jan 17;18(3):601-610. doi: 10.1016/j.celrep.2016.12.061. Cell Rep. 2017. PMID: 28099841 Free PMC article.
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Demo SD, et al. Cancer Res. 2007 Jul 1;67(13):6383-91. doi: 10.1158/0008-5472.CAN-06-4086. Cancer Res. 2007. PMID: 17616698
Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.
Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, Issakani SD, Molineaux S, Demo SD. Pray TR, et al. Among authors: demo sd. Drug Resist Updat. 2002 Dec;5(6):249-58. doi: 10.1016/s1368-7646(02)00121-8. Drug Resist Updat. 2002. PMID: 12531181 Review.
Molecular mechanisms of bortezomib resistant adenocarcinoma cells.
Suzuki E, Demo S, Deu E, Keats J, Arastu-Kapur S, Bergsagel PL, Bennett MK, Kirk CJ. Suzuki E, et al. Among authors: demo s. PLoS One. 2011;6(12):e27996. doi: 10.1371/journal.pone.0027996. Epub 2011 Dec 22. PLoS One. 2011. PMID: 22216088 Free PMC article.
Drug discovery in the ubiquitin regulatory pathway.
Wong BR, Parlati F, Qu K, Demo S, Pray T, Huang J, Payan DG, Bennett MK. Wong BR, et al. Among authors: demo s. Drug Discov Today. 2003 Aug 15;8(16):746-54. doi: 10.1016/s1359-6446(03)02780-6. Drug Discov Today. 2003. PMID: 12944097 Review.
28 results